The FDA on February 28, 2022, approved CARVYKTI® for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a Proteasome Inhibitor (PI), an Immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody. CARVYKTI® is a product of Janssen Biotech, Inc.
Bottom Ad
Advertisement
Subscribe
